Victory Capital Management Inc. lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL – Get Rating) by 2.1% in the first quarter, according to the company in its latest filing with the SEC. The company held 109,531 shares of the specialty pharmaceutical company after selling 2,389 shares during the period. Victory Capital Management Inc. owned approximately 0.32% of Collegium Pharmaceutical worth $1,952,000 at the end of the last quarter.
Other large investors have also changed their stake in the company. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Collegium Pharmaceutical by 52.2% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,161 shares of the specialty pharmaceutical company worth $42,000 after acquiring an additional 741 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $187,000. Euclidean Technologies Management LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth approximately $204,000. OneAscent Financial Services LLC raised its position in shares of Collegium Pharmaceutical by 5.5% in the fourth quarter. OneAscent Financial Services LLC now owns 11,774 shares of the specialty pharmaceutical company worth $220,000 after acquiring an additional 612 shares during the period. Finally, OneAscent Wealth Management LLC increased its position in Collegium Pharmaceutical shares by 5.2% in the fourth quarter. OneAscent Wealth Management LLC now owns 14,131 shares of the specialty pharmaceutical company worth $264,000 after acquiring an additional 700 shares during the period.
Changes to analyst ratings
COLL has been the subject of several research analyst reports. HC Wainwright downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “neutral” rating in a Monday, August 8 research report. StockNews.com downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a Thursday, May 19 research report. Two analysts have rated the stock with a hold rating and three have assigned the stock a buy rating. Based on data from MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $33.25.
Shares of Collegium Pharmaceutical down 2.1%
COLL stock opened at $18.80 on Friday. The company has a market capitalization of $641.57 million, a price/earnings ratio of -17.90, a PEG ratio of 0.24 and a beta of 0.88. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt ratio of 3.16. Collegium Pharmaceutical, Inc. has a 12-month low of $14.04 and a 12-month high of $22.89. The company has a 50-day moving average of $17.47 and a two-hundred-day moving average of $17.83.
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) last released quarterly earnings data on Tuesday, May 10. The specialty pharmaceutical company reported EPS of $0.42 for the quarter, missing analyst consensus estimates of $0.82 per ($0.40). The company posted revenue of $83.80 million in the quarter, compared to analyst estimates of $78.67 million. Collegium Pharmaceutical recorded a negative net margin of 11.24% and a negative return on equity of 2.12%. The company’s revenue was down 4.4% year-over-year. In the same quarter a year earlier, the company posted EPS of $0.41. As a group, analysts expect Collegium Pharmaceutical, Inc. to post earnings per share of 4.2 for the current fiscal year.
Collegium Pharmaceutical Company Profile
(Get a rating)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets drugs for pain management. Its portfolio includes Xtampza ER, an oral, extended-release, abuse-deterrent formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid therapy.
Read more
Want to see which other hedge funds hold COLL? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Collegium Pharmaceutical, Inc. (NASDAQ: COLL – Get Rating).
Get news and reviews for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
